Get started
Author

Leo W.K. Cheung

Observed names: L. W.‐K. Cheung, L.W. Cheung, Leo Cheung, Leo W. Cheung, Leo W. K. Cheung, Leo W.-K. Cheung, Leo WK Cheung, Leo WK. Cheung, Leo Wang-Kit Cheung, Leo Wk Cheung
ORCID: 0009-0004-8906-8366
Observed ORCID: 0009-0004-8906-8366
OpenAlex ID: A5076291201
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis
2020 · Ariela Noy, Sven de Vos, et al. · Blood Advances · 105
A Food Store Intervention Trial Improves Caregiver Psychosocial Factors and Children's Dietary Intake in Hawaii
2010 · Joel Gittelsohn, Vinutha Vijayadeva, et al. · Obesity · 96
PDF
Mammographic densities and circulating hormones: A cross-sectional study in premenopausal women
2005 · Jihae J. Noh, Gertraud Maskarinec, et al. · The Breast · 81
Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
2017 · Hsu-Ping Kuo, Scott A. Ezell, et al. · Molecular Cancer Therapeutics · 66
The Role of PIM1 in the Ibrutinib-Resistant ABC Subtype of Diffuse Large B-Cell Lymphoma
2015 · Hsu-Ping Kuo, Sidney Hsieh, et al. · Blood · 63
The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma.
2016 · Hsu-Ping Kuo, Scott A Ezell, et al. · PubMed · 55
Absence of BTK , BCL2 , and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax
2023 · Nitin Jain, Lisa J. Croner, et al. · Clinical Cancer Research · 51
PDF
Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK
2022 · Kamaldeep Dhami, Anirban Chakraborty, et al. · Science Signaling · 49
PDF
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study
2021 · Richard Greil, Alessandra Tedeschi, et al. · Annals of Hematology · 19
PDF
B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
2023 · Jennifer A. Woyach, Paolo Ghia, et al. · Clinical Cancer Research · 17
PDF
Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies
2022 · Jan A. Burger, Tadeusz Robak, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 14
Rarity of B-Cell Receptor Pathway Mutations in Progression-Free Patients With Chronic Lymphocytic Leukemia (CLL) During First-Line Versus Relapsed/Refractory (R/R) Treatment With Ibrutinib
2020 · Adrian Wiestner, Paolo Ghia, et al. · Blood · 9
Combination of Ibrutinib and BCL-2 or SYK Inhibitors in Ibrutinib Resistant ABC-Subtype of Diffuse Large B-Cell Lymphoma
2014 · Hsu-Ping Kuo, Richard Crowley, et al. · Blood · 9
Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE)
2020 · Jan A. Burger, Tadeusz Robak, et al. · Blood · 5
Ibrutinib Decreases Obinutuzumab‐induced Secretion of Cytokines Associated With Infusion‐related Reactions in Patients With Cll: Analysis From the Illuminate Study
2019 · R. Greil, A. Tedeschi, et al. · Hematological Oncology · 4
Kinase‐dead Bruton’s Tyrosine Kinase (btk) C481f/y Mutants Confer Ibrutinib Resistance Through Activation of Hematopoietic Cell Kinase (hck)
2021 · K. Dhami, L. W.‐K. Cheung, et al. · Hematological Oncology · 2
Data from Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax
2024 · Nitin Jain, Lisa J. Croner, et al. · 1
Abstract 3072: Combination of ibrutinib and corticosteroids in B-cell non-Hodgkin lymphomas (NHL)
2016 · Hsu-Ping Kuo, Sidney Hsieh, et al. · Cancer Research · 1
Supplementary Table S1 from B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
2025 · Jennifer A. Woyach, Paolo Ghia, et al.
PDF
Supplementary table S2 from B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
2025 · Jennifer A. Woyach, Paolo Ghia, et al.
PDF
Supplementary Table S3 from B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
2025 · Jennifer A. Woyach, Paolo Ghia, et al.
PDF
Supplementary Methods S1 from B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
2025 · Jennifer A. Woyach, Paolo Ghia, et al.
PDF
Systematic molecular profiling to identify determinants of response to ibrutinib
2025 · Negin Karisani, Amit Sud, et al. · Blood
PDF
First-line ibrutinib + venetoclax shows benefit across genomic subgroups in patients with chronic lymphocytic leukemia (CLL): Results from Phase 2 captivate study and Phase 3 glow study
2025 · Leo Cheung, Shiquan Wu, et al. · Blood
PDF
The Impact of Therapeutic Selective Pressure on the Evolutionary Landscape of Chronic Lymphocytic Leukemia
2024 · Negin Karisani, Amit Sud, et al. · Blood
PDF
Works count: 64
Citation count: 647
H-index: 11
I10-index: 11
Year
Topic
Type